Revisiting dezocine for opioid use disorder: A narrative review of its potential abuse liability

被引:1
|
作者
Barr, Gordon A. [1 ,2 ,3 ]
Schmidt, Heath D. [4 ,5 ]
Thakrar, Ashish P. [6 ,7 ]
Kranzler, Henry R. [5 ,8 ]
Liu, Renyu [2 ,9 ]
机构
[1] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Anesthesiol & Crit Care Med, Perelman Sch Med, Philadelphia, PA 19104 USA
[3] Univ Penn, Dept Psychol, Philadelphia, PA 19104 USA
[4] Univ Penn, Sch Nursing, Dept Biobehav Hlth Sci, Philadelphia, PA 19104 USA
[5] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA
[6] Univ Penn, Perelman Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA
[7] Univ Penn, Penn Ctr Addict Med & Policy, Perelman Sch Med, Philadelphia, PA 19104 USA
[8] Crescenz VAMC, Vet Integrated Serv Network 4, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA
[9] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA
关键词
biased mu-opioid ligand; dependence; dezocine; drug discrimination; drug self-administration; opioid use disorder; RESPIRATORY DEPRESSION; CELLS;
D O I
10.1111/cns.70034
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Aims: Opioid use disorder (OUD) remains a serious public health problem. Opioid maintenance treatment is effective but under-utilized, hard to access under existing federal regulations, and, once patients achieve OUD stability, challenging to discontinue. Fewer than 2% of persons with OUD stop using opioids completely. There have been calls from public advocacy groups, governmental agencies, and public health officials for new treatments for OUD. Dezocine, a non-scheduled opioid previously used in the United States and currently widely prescribed in China for pain management, could be a candidate for a novel OUD treatment medication in the U.S. Nonetheless, to date, there have been no reviews of the clinical and preclinical literature detailing dezocine's abuse potential, a key consideration in assessing its clinical utility. Discussion: There are no English language reports of human abuse, dependence, or overdose of dezocine, despite years of extensive clinical use. There are a few case reports of dezocine abuse in the Chinese literature, but there are no reports of overdose deaths. Dezocine is perceived as an opioid and is "liked" by opioid-experienced human and non-human primates, properties that are not dose-dependent and are mitigated by ceiling effects-higher doses do not result in more "liking." There is little withdrawal, spontaneous or precipitated, in humans, monkeys, rats, or mice treated chronically with dezocine alone. However, at some doses, dezocine can precipitate withdrawal in humans and monkeys dependent on other opioids. In rodents, dezocine reduces the severity of morphine withdrawal and the rewarding properties of other opioids. Conclusions: Although dezocine is reinforcing in humans and monkeys with prior or concurrent opioid use within a restricted dose range, there are only a few anecdotal reports of dezocine abuse despite of the long history of use in humans. Given the evidence of dezocine's limited abuse potential, it could be useful both as a treatment for OUD. However, in-depth studies would be required for dezocine to be re-considered for clinical use.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Gabapentin increases the abuse liability of alcohol alone and in combination with oxycodone in participants with co-occurring opioid and alcohol use disorder
    Castillo, F.
    Jones, J. D.
    Luba, R. R.
    Mogali, S.
    Foltin, R. W.
    Evans, S. M.
    Comer, S. D.
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2022, 221
  • [32] Exploring the role of mu opioid receptors in the therapeutic potential and abuse liability of (S)-ketamine
    Levinstein, Marjorie R. R.
    Michaelides, Michael
    NEUROPSYCHOPHARMACOLOGY, 2024, 49 (01) : 315 - 316
  • [33] Exploring the role of mu opioid receptors in the therapeutic potential and abuse liability of (S)-ketamine
    Marjorie R. Levinstein
    Michael Michaelides
    Neuropsychopharmacology, 2024, 49 : 315 - 316
  • [34] A Review of Leveraging Artificial Intelligence to Predict Persistent Postoperative Opioid Use and Opioid Use Disorder and its Ethical Considerations
    Gabriel, Rodney A.
    Park, Brian H.
    Hsu, Chun-Nan
    Macias, Alvaro A.
    CURRENT PAIN AND HEADACHE REPORTS, 2025, 29 (01)
  • [35] Polydrug abuse: A review of opioid and benzodiazepine combination use
    Jones, Jermaine D.
    Mogali, Shanthi
    Comer, Sandra D.
    DRUG AND ALCOHOL DEPENDENCE, 2012, 125 (1-2) : 8 - 18
  • [36] Genetic and epigenetic studies of opioid abuse disorder - the potential for future diagnostics
    Abdulmalek, Sarah
    Hardiman, Gary
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2023, 23 (05) : 361 - 373
  • [37] Craving and opioid use disorder: A scoping review
    Kleykamp, Bethea A.
    De Santis, Marta
    Dworkin, Robert H.
    Huhn, Andrew S.
    Kampman, Kyle M.
    Montoya, Ivan D.
    Preston, Kenzie L.
    Ramey, Tanya
    Smith, Shannon M.
    Turk, Dennis C.
    Walsh, Robert
    Weiss, Roger D.
    Strain, Eric C.
    DRUG AND ALCOHOL DEPENDENCE, 2019, 205
  • [38] Stress and opioid use disorder: A systematic review
    MacLean, R. Ross
    Armstrong, Jessica L.
    Sofuoglu, Mehmet
    ADDICTIVE BEHAVIORS, 2019, 98
  • [39] Psychoactive plant derivatives (ayahuasca, ibogaine, kratom) and their application in opioid withdrawal and use disorder - a narrative review
    Arenson, Alexandra
    Campbell, Cynthia I.
    Remler, Ilan
    JOURNAL OF ADDICTIVE DISEASES, 2024, 42 (03) : 253 - 263
  • [40] Considerations and limitations of buprenorphine prescribing for opioid use disorder in the intensive care unit setting: A narrative review
    Erstad, Brian L.
    Glenn, Melody J.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2024, 81 (06) : 171 - 182